Nvidia and TSMC to unveil first domestic wafer for Blackwell chips, Axios reports
Investing.com - Stifel has raised its price target on Johnson & Johnson (NYSE:JNJ) to $190.00 from $165.00 while maintaining a Hold rating on the healthcare giant’s stock.
The price target increase follows Johnson & Johnson’s better-than-expected third-quarter 2025 earnings results, where the company delivered above-consensus sales and EPS performance along with positive business outlook commentary.
Stifel noted that Johnson & Johnson management expressed optimism about the remainder of 2025 and confidence that the business is now in an "accelerated cycle of growth." The company expects continued MedTech growth acceleration as new product innovations like the Shockwave C2 Aero catheter and Tecnis intraocular lens approach launch.
Johnson & Johnson plans to submit its Ottava surgical robot to the FDA in early 2026, with Stifel anticipating approval in the second half of 2026 at the earliest, based on similar regulatory timelines seen with competitors.
Stifel has revised its projections upward, now forecasting 5.2% reported growth year-over-year for 2026, up from its previous estimate of 4.1%, while its full-year 2026 adjusted EPS projection has been raised to $11.42 per share from $11.39.
In other recent news, Johnson & Johnson reported its third-quarter earnings for 2025, surpassing analysts’ expectations. The company achieved an earnings per share of $2.80, which was higher than the forecasted $2.76. Additionally, Johnson & Johnson’s revenue reached $23.99 billion, exceeding the anticipated $23.76 billion. These results highlight the company’s strong financial performance in the recent quarter. Analyst firms have not provided any upgrades or downgrades following this earnings announcement. The reported figures are significant for investors as they reflect the company’s ability to outperform market predictions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.